Company Insights

SRXH customer relationships

Explore interactive graphBrowse insights index
SRXH customer relationship map

SRx Health Solutions (SRXH): E‑commerce partners are the revenue engine — and the concentration risk

SRx Health Solutions operates the Halo pet health and wellness business, monetizing primarily through the sale of premium pet food and wellness products to retail and e‑commerce partners rather than a direct‑to‑consumer storefront. Revenue flows through digital reseller channels—notably Amazon and Chewy—and through select retail platforms, after the company exited its direct storefront and scaled back brick‑and‑mortar exposure. For investors, the story is straightforward: brand‑led product sales routed through third‑party channels provide scale, while extreme customer concentration and channel dependency create the principal risk vector. Learn more about customer relationships at Null Exposure: https://nullexposure.com/

One sentence view on the business model

SRx Health sells core Halo products into reseller and retailer channels (Digital and Retail), relies on partner platforms for customer access and repeat purchases, and captures margin between product cost and wholesale pricing; contractual posture is typical supplier/reseller with limited direct consumer control after the DTC exit.

How the customer map shapes operating constraints

The company’s filings reveal a North America focus, with only selective activity in Asia. International sales are a smaller portion of revenue, so geographic risk is concentrated in the U.S. market. The 10‑K also discloses severe customer concentration: three customers represented 98% of accounts receivable and 88% of gross sales in FY2025, which elevates counterparty risk and supplier bargaining exposure. The business operates as a seller to resellers—the majority of net sales flow through e‑commerce partner websites—so distribution and platform dynamics (search, buy box, promotions) directly affect top line and margin. The company has terminated its direct‑to‑consumer channel (halopets.com exited June 2024) and strategically exited select physical stores, concentrating commerce on third‑party platforms and partners. These are company‑level signals derived from the FY2025 filing.

Channel partners and what each relationship contributes

Amazon

SRx lists Amazon among its primary e‑commerce partner websites and classifies sales to Amazon within the Digital revenue channel. According to SRx Health’s FY2025 Form 10‑K, Amazon is an explicit digital distribution partner that drives repeat online purchases and contributes to the Digital category of revenue.

Chewy

Chewy is named alongside Amazon as a key online retailer in the company’s Digital channel; SRx groups sales to Chewy under its digital reseller revenue classification. The FY2025 10‑K states Chewy as a core online retail partner for the Halo product lineup.

Petflow

Petflow is included in the roster of e‑commerce partners that carry Halo products, indicating a role as an online reseller channel. SRx’s FY2025 10‑K lists Petflow among e‑commerce partner websites used to distribute the Halo line.

Thrive Market

Thrive Market appears in the company’s disclosure of e‑commerce partner websites, representing another online retail channel for Halo products as reported in the FY2025 10‑K.

Vitacost

Vitacost is likewise cited among the company’s e‑commerce partners, confirming that SRx distributes Halo products through health‑oriented online retailers, per the FY2025 Form 10‑K.

Pet Supplies Plus

SRx notes it strategically exited Petco and Pet Supplies Plus stores while continuing online sales via those platforms, indicating that although the company pulled back from physical shelf space, it retains online distribution through those retail brands. The FY2025 filing documents the exit from store footprints while maintaining platform presence for online transactions.

Petco

Petco is referenced in the same context as Pet Supplies Plus: SRx exited physical store placements but continues to sell through Petco’s online channels, per the FY2025 Form 10‑K.

(Each relationship summary above is drawn from SRx Health Solutions’ Form 10‑K for the fiscal year ended September 30, 2025.)

Why these relationships matter now: concentration, control, and margin pressure

  • Concentration is the central risk. The FY2025 filing shows three customers accounted for 98% of accounts receivable and 88% of gross sales, which is a critical company‑level signal that revenue and cash collection hinge on a handful of partners. Loss of one large partner would cause immediate cash flow stress.
  • Reseller model reduces pricing control. By routing sales through Amazon, Chewy, and other resellers, SRx cedes consumer interface and promotional control to platforms, which can compress margins through platform fees, promotions, and feature allocations.
  • DTC exit changes the leverage balance. Exiting halopets.com (June 2024) and physical stores shifts customer acquisition and retention to partners; this reduces marketing spend but also diminishes brand control and recurring customer insights.
  • Geography is concentrated in North America. International operations are limited; therefore, any U.S. retail or platform disruption disproportionately affects SRx’s revenue.

For a deeper read on customer exposures and supplier mapping, visit Null Exposure’s home page: https://nullexposure.com/

What investors should monitor (practical checklist)

  • Quarterly revenue by customer and accounts receivable concentration metrics to detect any shift among the top three counterparties.
  • Payment terms and receivable aging for the largest partners; a growing AR days or disputed receivables signal cash‑flow stress.
  • Channel mix trends—percentage of sales to Amazon vs Chewy vs other partners—and any changes in wholesale pricing or promotional liability.
  • Inventory turnover and any buildup tied to platform promotion schedules.
  • Any announcements of renewed DTC efforts or new distribution agreements that diversify counterparty risk.

Bottom line and action

SRx Health monetizes premium Halo products through a reseller and retail partner model that scales distribution quickly but concentrates risk with a very small set of counterparties. Investors should price in both the upside of brand distribution through major platforms and the downside of concentrated customer exposure. For actionable customer relationship insight and continuous monitoring, check Null Exposure: https://nullexposure.com/

Key takeaway: distribution partnerships power SRx’s revenue today; counterparty concentration and limited direct consumer control are the principal operational constraints investors must track.